Phase III Manufacturing Suite Now Operational — 60% Capacity Increase

Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%. The suite features 4 new automated SPPS reactors and a dedicated lyophilization suite capable of processing 200L batches.

← Back to News
Newsletter

Stay Ahead in
Peptide Science

Join 5,000+ pharmaceutical and biotech professionals who receive our monthly newsletter — covering product launches, regulatory updates, and industry insights.

  • New product launches & catalog updates
  • Regulatory news & compliance updates
  • Industry trends & market insights
  • Company milestones & partnerships

Subscribe to Our Newsletter

Monthly digest, no spam. Unsubscribe anytime.

By subscribing, you agree to our Privacy Policy. No spam, ever.